The U.S. Supreme Court has agreed to hear the Biden administration’s challenge to Purdue Pharma’s bankruptcy settlement. This settlement would provide legal immunity to the Sackler family, Purdue’s owners, in exchange for their payment of up to $6 billion to settle numerous lawsuits. These legal actions, filed by states, individuals, hospitals, and others, pertain to Purdue’s alleged misleading promotion of OxyContin, a potent pain medication that has played a significant role in the opioid epidemic.
The Supreme Court has decided to halt bankruptcy proceedings concerning Purdue Pharma and its affiliates. The court plans to conduct oral arguments in December as it reviews the administration’s appeal. This move has caused a delay in the implementation of the settlement. The Supreme Court’s upcoming term begins in October.
The settlement is designed to grant immunity to the Sackler family while requiring them to contribute billions towards resolving the lawsuits linked to the opioid crisis. The legal dispute hinges on whether the U.S. bankruptcy law permits such protection for non-bankrupt entities like the Sacklers.
The Biden administration and several states initially contested the settlement, but most states withdrew their opposition after the Sacklers committed to higher contributions. The administration’s appeal challenges the legality of extending bankruptcy protections to non-debtors like the Sacklers.
Various stakeholders have responded differently to the settlement review. A group representing over 60,000 individuals who filed personal injury claims linked to Purdue’s opioid products expressed support for the settlement. They highlighted the importance of the settlement for victim compensation and the broader efforts to address the opioid crisis.
The Supreme Court’s decision to review the Purdue Pharma bankruptcy settlement marks a significant development in the ongoing battle against the opioid epidemic. The outcome of this case could influence future legal actions and strategies concerning pharmaceutical companies’ accountability for their role in public health crises.
